{
    "organizations": [],
    "uuid": "8680fdf9834beedbf1bd55a4cd7557c35e398a9c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-merck-says-its-selumetinib-granted/brief-merck-says-its-selumetinib-granted-orphan-drug-designation-by-fda-for-neurofibromatosis-type-1-idUSASB0C5WB",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 43 AM / Updated 10 minutes ago BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1 Reuters Staff Feb 15 (Reuters) - Merck & Co Inc: * SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1 * MERCK & CO INC - ‍FDA GRANTED ORPHAN DRUG DESIGNATION FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1​ * MERCK & CO INC - PHASE II TRIAL RESULTS FOR SELUMETINIB ARE EXPECTED LATER IN 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-02-15T13:42:00.000+02:00",
    "crawled": "2018-02-15T13:58:31.043+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "say",
        "selumetinib",
        "granted",
        "orphan",
        "drug",
        "designation",
        "fda",
        "neurofibromatosis",
        "type",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "merck",
        "co",
        "inc",
        "selumetinib",
        "granted",
        "orphan",
        "drug",
        "designation",
        "fda",
        "neurofibromatosis",
        "type",
        "merck",
        "co",
        "inc",
        "granted",
        "orphan",
        "drug",
        "designation",
        "selumetinib",
        "mek",
        "inhibitor",
        "treatment",
        "neurofibromatosis",
        "type",
        "merck",
        "co",
        "inc",
        "phase",
        "ii",
        "trial",
        "result",
        "selumetinib",
        "expected",
        "later",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}